Financial Data and Key Metrics Changes - Total revenue for 2023 was $143.3 million, an 11% decrease compared to 2022, with ex-COVID revenue decreasing 4% [36] - Q4 revenue was $32.7 million, representing a 26% year-over-year decrease, and a 23% decline when excluding COVID-related revenue from Q4 2022 [41] - Adjusted EBITDA for Q4 2023 was $700,000, down from $1.7 million in the prior year, but increased sequentially by $3.8 million from Q3 [60] Business Line Data and Key Metrics Changes - Cell processing platform revenue for 2023 declined 4% to $65.8 million, while biopreservation media revenue decreased by 6% [36] - Freezer and thaw platform revenue declined 23% or $15.1 million from 2022, primarily due to a difficult capital equipment environment [37] - Biostorage and services platform revenue for Q4 was $6.6 million, a decrease of 1% year-over-year, but increased 26% when excluding COVID-related revenue [42] Market Data and Key Metrics Changes - The top 20 media customers accounted for 78% of media revenue in 2023, up slightly by 1% year-over-year [31] - Distributors accounted for 40% of total media revenue in 2023, compared to 38% in 2022 [31] - The company estimates that its biopreservation media is embedded in more than 70% of over 230 active US commercially sponsored clinical trials [39] Company Strategy and Development Direction - The company is divesting its freezer product lines to refocus on higher-margin recurring revenue streams [29][35] - The company expects to close the divestiture transactions within the next 45 to 60 days, which will improve overall financial performance and margin profile [32][37] - The company aims to leverage its market position in biopreservation media to drive adoption of other tools and services in its portfolio [120] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding improving market conditions in the second half of 2024, despite a challenging environment in 2023 [40][46] - The company anticipates 2024 revenue guidance to range from $95.5 million to $100 million, reflecting an overall growth of 2% to 7% [61] - Management noted that macro headwinds may be subsiding, with early signs of stabilization in the CGT industry [30][35] Other Important Information - The company reported a GAAP net loss of $13.4 million in Q4, with adjusted operating loss of $9.3 million [44] - Cash and marketable securities balance at December 31, 2023, was $52.3 million, up from $42.2 million at September 30, 2023 [45] - The company is currently consolidating its two Boston area facilities, expected to save approximately $0.5 million in annual operating costs [56] Q&A Session Summary Question: Confidence in freezer sale completion - Management expressed 75% to 80% confidence that the freezer sales will be completed within the expected timeframe [20][21] Question: Steps taken to achieve positive EBITDA - Management highlighted a reduction in force, increased self-processing revenue, and control over discretionary expenses as key steps [14] Question: Potential revenue from cell and gene therapies - Management explained that revenue growth from new therapies will depend on ramp-up periods and the nature of approvals [16][17] Question: Media revenue growth expectations - Management indicated that media revenue is expected to grow in the second half of the year, with a focus on understanding customer needs [23][80] Question: Impact of freezer business on adjusted EBITDA - Management noted that the freezer business had a significant impact on adjusted EBITDA, but specific figures were not disclosed [69][101]

Core Insights - BioLife Solutions, Inc. reported a quarterly loss of $0.01 per share, outperforming the Zacks Consensus Estimate of a loss of $0.06, and showing improvement from a loss of $0.30 per share a year ago, resulting in an earnings surprise of 83.33% [1] - The company achieved revenues of $22.71 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 6.29%, although this represents a decline from year-ago revenues of $32.73 million [2] - BioLife Solutions has consistently surpassed consensus EPS estimates over the last four quarters, indicating a positive trend in earnings performance [2] Financial Performance - The company has shown a significant improvement in earnings, with a surprise of 77.78% in the previous quarter, where it reported a loss of $0.02 per share against an expected loss of $0.09 [1] - The current consensus EPS estimate for the upcoming quarter is -$0.06, with projected revenues of $21.76 million, and for the current fiscal year, the estimate is -$0.13 on revenues of $95.71 million [7] Market Position - BioLife Solutions shares have underperformed the market, losing approximately 7.6% since the beginning of the year, while the S&P 500 has gained 1.2% [3] - The company's Zacks Rank is currently 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6] Industry Context - The Medical - Products industry, to which BioLife Solutions belongs, is currently ranked in the bottom 48% of over 250 Zacks industries, indicating potential challenges in overall industry performance [8] - The performance of BioLife Solutions may be influenced by the broader industry outlook, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Core Insights - BioLife Solutions reported a 7% sequential increase in Cell Processing revenue to $20.3 million in Q4 2024, with a 12% year-over-year growth to $73.5 million for the full year [1][10] - The company achieved a GAAP gross margin of 60% and a non-GAAP adjusted gross margin of 63% for Q4 2024, reflecting improvements from the previous year [1][10] - BioLife expects 2025 Cell Processing revenue to range from $86.5 million to $89.0 million, representing an 18% to 21% increase over 2024, with total revenue guidance of $95.5 million to $99.0 million, up 16% to 20% [1][11] Financial Performance - Total revenue for Q4 2024 was $22.7 million, a 31% increase from $17.4 million in Q4 2023 [10] - The company reported a GAAP net loss of $2.0 million for Q4 2024, an improvement from a loss of $7.2 million in Q4 2023 [10] - Adjusted EBITDA for Q4 2024 was $4.0 million, or 18% of total revenue, compared to $3.7 million, or 21% of revenue, in Q4 2023 [10][27] Business Strategy - The company divested non-core product lines, including its freezer and biostorage businesses, to enhance gross margin and adjusted EBITDA margin [2][6] - BioLife aims to deepen relationships with biopreservation customers and increase adoption of its broader cell processing product lines through cross-selling [3] - The focus remains on strategically enhancing the cell processing portfolio to strengthen market leadership and deliver long-term value [3] Operational Highlights - BioLife processed 19 new U.S. FDA Master File cross references for biopreservation media in 2024, bringing the cumulative total to 769 [6] - The biopreservation media was embedded in 17 unique approved cell and gene therapies as of December 31, 2024, with expectations for additional approvals in the next 12 months [6] - The company ended 2024 with a cash position exceeding $100 million, bolstered by the sales of SciSafe and CBS [2][6]

BOTHELL, Wash., Feb. 20, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2024 fourth quarter and full year financial results will be released on March 3, 2025 pre-market. The Company will host a conference call and live webcast at 8:00am ET (5:00am PT) that day. Management will provide an overview of the Company's financial results and give a general business ...

Core Viewpoint - The article emphasizes the importance of identifying and maintaining stock price trends for successful short-term investing, highlighting BioLife Solutions, Inc. (BLFS) as a strong candidate for trend investors due to its recent price performance and fundamental strength [1][4][6]. Group 1: Price Performance - BLFS has experienced a solid price increase of 19.7% over the past 12 weeks, indicating strong investor interest [4]. - The stock has also maintained a price increase of 2.3% over the last four weeks, suggesting that the upward trend is still intact [5]. - Currently, BLFS is trading at 82.2% of its 52-week high-low range, indicating a potential breakout opportunity [5]. Group 2: Fundamental Strength - BLFS holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. - The Zacks Rank system has a proven track record, with Zacks Rank 1 stocks generating an average annual return of +25% since 1988, further supporting the investment case for BLFS [7]. Group 3: Investment Strategy - The article suggests that investors should consider other stocks that pass the "Recent Price Strength" screen, which identifies stocks with sufficient fundamental strength to maintain their upward trends [3][8]. - The Zacks Research Wizard tool is recommended for backtesting stock-picking strategies, allowing investors to evaluate the effectiveness of their approaches [9].

Company Performance - BioLife Solutions, Inc. (BLFS) shares have increased by 9.8% over the past month and have reached a new 52-week high of $29.46 [1] - Year-to-date, the stock has gained 9.8%, outperforming the Zacks Medical sector, which has seen a decline of 0.6%, and the Zacks Medical - Products industry, which has returned 20.9% [1] Earnings and Valuation - The company has a strong record of positive earnings surprises, having beaten earnings consensus estimates in the last four quarters [2] - In the latest earnings report on November 12, 2024, BioLife Solutions reported an EPS of $-0.02, surpassing the consensus estimate of $-0.09, and beat the revenue estimate by 21.98% [2] Valuation Metrics - BioLife Solutions has a Value Score of F, while its Growth and Momentum Scores are A and B, respectively, resulting in a VGM Score of B [5] - The Zacks Rank for BioLife Solutions is 2 (Buy), indicating rising earnings estimates and suggesting potential for the stock in the near future [6] Industry Comparison - The Medical - Products industry is positioned in the top 35% of all industries, indicating favorable conditions for both BioLife Solutions and its peer, Phibro Animal Health Corporation (PAHC) [9] - PAHC has a Zacks Rank of 2 (Buy) with strong earnings performance, having beaten consensus estimates by 52.17% in the last quarter [8]

Group 1 - BioLife Solutions, Inc. (BLFS) is a notable stock within the Medical sector, currently ranked 2 in the Zacks Sector Rank, which includes 1010 companies [2][3] - The Zacks Consensus Estimate for BLFS' full-year earnings has increased by 31.5% in the past quarter, indicating improved analyst sentiment and earnings outlook [4] - Year-to-date, BLFS has returned approximately 7.2%, outperforming the Medical group average loss of about 2.1% [4] Group 2 - BioLife Solutions, Inc. is part of the Medical - Products industry, which consists of 82 stocks and is currently ranked 139 in the Zacks Industry Rank, with an average gain of 19% this year [6] - In comparison, Ginkgo Bioworks Holdings, Inc. (DNA) has returned 34.2% year-to-date and is part of the Medical - Biomedical and Genetics industry, which has seen a decline of 10.3% [5][6] - Investors should monitor both BioLife Solutions, Inc. and Ginkgo Bioworks Holdings, Inc. for potential continued strong performance in the Medical sector [7]

Core Viewpoint - The article emphasizes the importance of identifying and maintaining stock price trends for successful short-term investing, highlighting the use of a specific screening strategy to find stocks with strong fundamentals and positive price momentum [1][2][3]. Group 1: Stock Performance - BioLife Solutions, Inc. (BLFS) has shown a solid price increase of 16.5% over the past 12 weeks, indicating investor confidence in its potential upside [4]. - The stock has also maintained a price increase of 3.7% over the last four weeks, suggesting that the upward trend is still intact [5]. - BLFS is currently trading at 90.3% of its 52-week high-low range, indicating a potential breakout opportunity [5]. Group 2: Fundamental Strength - BLFS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, which are critical for near-term price movements [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term performance [7]. - The Zacks Rank system has a proven track record, with Zacks Rank 1 stocks averaging an annual return of +25% since 1988, underscoring the reliability of this ranking system [7]. Group 3: Investment Strategy - The article suggests that investors should consider other stocks that pass the "Recent Price Strength" screen, which identifies stocks with strong fundamentals and positive price trends [8]. - The Zacks Research Wizard tool is recommended for backtesting stock-picking strategies, allowing investors to evaluate the effectiveness of their approaches [9].

Core Insights - BioLife Solutions reported a 7% sequential increase in fourth quarter Cell Processing revenue, reaching $20.3 million, and a full year revenue of $73.5 million, exceeding the high end of previously raised guidance [1][2][8] - The company experienced its fifth consecutive quarter of sequential revenue growth in the Cell Processing platform, indicating strong operational execution and strategic focus [2][8] - The divestiture of its freezer and biostorage businesses has streamlined operations, allowing BioLife to concentrate on its core competencies in the cell and gene therapy market [2][4] Financial Performance - Preliminary unaudited revenue for the fourth quarter of 2024 was $22.7 million, a 31% increase from $17.4 million in the same quarter of 2023 [8] - For the full year 2024, total revenue was $82.3 million, reflecting an 8% increase from $75.9 million in 2023 [8] - The Cell Processing platform revenue for 2024 was $73.5 million, up 12% from the previous year, while the Evo and Thaw platform revenue decreased by 14% to $8.7 million [8] Strategic Focus - The company emphasizes its role in biopreservation solutions, which are embedded in 17 approved therapies, highlighting its importance in enabling lifesaving therapies [2] - Looking ahead to 2025, BioLife aims to leverage its strong balance sheet and core business momentum to achieve sustainable growth and profitability [2]

BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (Nasdaq: RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. "Tony is highly respected ...